Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream

Radiology and Oncology

Volumn 44, Issue 4, 2010, Pages 265-266

  Ocvirk, Janja ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; PHYTOMENADIONE; RENCOVAL K1; UNCLASSIFIED DRUG;

CASE REPORT; COLORECTAL CANCER; DRUG MECHANISM; HUMAN; LETTER; PAPULE; PROPHYLAXIS; RASH; SKIN TOXICITY;

EID: 78649273546     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/v10019-010-0036-6     Document Type: Letter

References (11)

1. Segaert S, van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-33.
2. van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic color-ectal cancer. N Engl J Med 2009; 360: 1408-17.
3. Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8.
4. Lacouture ME. Insights into the pathophysiology and management of der-matologic toxicities to EGFR-targeted therapies in colorectal cancer. Cancer Nurs 2007; 30: S17-26.
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
6. Erbitux. Summary of product characteristics. Available at http://www.emea. europa.eu/humandocs/PDFs/EPAR/erbitux/H-558-PI-en.pdf [Accessed July 14, 2009]
7. Ocvirk J, Rebersek M. Management of cutaneous side effects of cetuximab therapy with vitamin K1 cream. Radiol Oncol 2008; 42: 215-24.
8. The international response to Helsinki VI-The WMA's Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects, as adopted by the 52nd WMA General Assembly. Edinburgh; October 2000. Available at http://www.wma.net/en/20activities/10ethics/10helsinki/index.html [Accessed July 16, 2009]
9. Tan EH, Chan A. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother 2009; 43: 1658-66.
10. Li TH, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Targ Oncol 2009; 4: 107-19.
11. Ocvirk J, Rebersek M. Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream. [Abstract]. J Clin Oncol 2009; 27(Suppl): e15087.